AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of acute and breakthrough pain in the United States and internationally. The company develops product candidates based on proprietary NanoTab technology, a non-invasive, sublingual dosage form that delivers highly lipophilic drugs with consistent pharmacokinetics. Its products include ARX-01, a Sufentanil NanoTab PCA System that completed Phase II clinical trial for acute post-operative pain; ARX-02, a Sufentanil NanoTab BTP Management System, which completed Phase II clinical trial for the treatment of cancer breakthrough pain; and ARX-03, a Sufentanil/Triazolam NanoTab that completed Phase II clinical trial is designed to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician’s office. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.